Innate Pharma (IPHA) Stock Price, News & Analysis

Company Overview

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca. In addition to monalizumab, Innate Pharma’s pipeline includes multiple early- to late-stage candidates such as IPH5201 (anti-TIM-4) and IPH6101 (anti-IL-1RAP), which aim to broaden therapeutic options across solid tumors and hematological malignancies. These assets reflect Innate Pharma’s commitment to advancing precision immunotherapies through strategic partnerships and rigorous clinical development.

Since its inception, Innate Pharma has established a global footprint, conducting multi-center clinical trials across Europe and North America. The company’s research facilities in Marseille support a multidisciplinary team of scientists, clinicians and regulatory experts focused on biomarker-driven approaches. Through collaborations with major pharmaceutical companies, Innate Pharma leverages complementary expertise to accelerate the translation of its discovery efforts into the clinic.

Led by a management team with deep experience in biotechnology product development, Innate Pharma maintains a strategic focus on unlocking the potential of innate immunity for cancer treatment. The company’s operations benefit from a robust intellectual property portfolio and a track record of forging alliances that enhance its capacity to deliver innovative oncology solutions to patients worldwide.

Key Stats

• Today's Range: $2.07 to $2.21
• 50-Day Range: $1.78 to $2.28
• 52-Week Range: $1.29 to $3.51
• Volume: 15,152 shs
• Average Volume: 12,802 shs
• Market Capitalization: $201.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Hold

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 42% of companies evaluated by MarketBeat, and ranked 657th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Innate Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

Upside Potential

Innate Pharma has a consensus price target of $6.50, representing about 196.8% upside from its current price of $2.19.

Amount of Analyst Coverage

Innate Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Innate Pharma has a P/B Ratio of 19.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the outstanding shares of Innate Pharma have been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently increased by 4.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.05% of the outstanding shares of Innate Pharma have been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently increased by 4.96%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.16% of the stock of Innate Pharma is held by institutions.

IPHA Stock Analysis - Frequently Asked Questions

How have IPHA shares performed this year?

Innate Pharma's stock was trading at $1.84 at the start of the year. Since then, IPHA shares have increased by 19.0% and is now trading at $2.19.

When did Innate Pharma IPO?

Innate Pharma (IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Innate Pharma?

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

Company Calendar

• Today: 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPHA
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: 33-4-30-30-30-30
• Fax: N/A
• Employees: 220
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Innate Pharma: $6.50
• High Price Target: $11.00
• Low Price Target: $2.00
• Potential Upside/Downside: +214.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 3.52
• Current Ratio: 2.21
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $21.77 million
• Price / Sales: 8.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 18.82

Miscellaneous

• Outstanding Shares: 92,180,000
• Free Float: 62,787,000
• Market Cap: $190.81 million
• Optionable: Not Optionable
• Beta: 0.04